The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, randomized, global phase 3 study to assess the efficacy and safety of intratumoral (IT) INT230-6 (SHAO, vinblastine, cisplatin) as monotherapy compared with standard of care systemic chemotherapy in adults with locally recurrent, inoperable, or metastatic soft tissue sarcomas (STS; INVINCIBLE-3).
 
Sant Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Counterpoint; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Abdul Razak
Employment - Princess Margaret Cancer Center
 
James Hu
No Relationships to Disclose
 
Arun Singh
Leadership - Certis Oncology Solutions
Stock and Other Ownership Interests - Certis Oncology Solutions
Honoraria - Galvanize Therapeutics
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Ipsen; Lilly
Speakers' Bureau - AADi; Daiichi Sankyo; Deciphera; Eisai; Lilly; MJH Life Sciences; Novartis; RAIN Therapeutics (Inst); Scripps Health; SpringWorks Therapeutics; TRACON Pharma (Inst)
Research Funding - Ayala Pharmaceuticals (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); deciphera (Inst); Intensity Therapeutics (Inst); Lilly (Inst); Nanocarrier (Inst); Polaris (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Deciphera; Eisai; Galvanize Therapeutics; Lilly; Novartis
Other Relationship - Certis Oncology Solutions
 
Kirsten Leu
Employment - Nebraska Cancer Specialists
 
David Liebner
Consulting or Advisory Role - AADi
Patents, Royalties, Other Intellectual Property - Co-holder of 2 patents ("Methods for Predicting Prognosis") that has been licensed to a private company, MatchTX, LLC.
 
Margaret von Mehren
Honoraria - Boehringer Ingelheim; Deciphera
Consulting or Advisory Role - deciphera; Von Pfeffel Pharma
Research Funding - ASCO (Inst); Cogent Biosciences (Inst); Deciphera (Inst); IDRx (Inst); Novartis (Inst); Sumitomo Pharma Oncology (Inst); Theseus (Inst)
Patents, Royalties, Other Intellectual Property - cell line
Travel, Accommodations, Expenses - Boehringer Ingelheim; deciphera
Other Relationship - NCCN
 
Daniel Pink
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Deciphera (Inst); PharmaMar (Inst); SpringWorks Therapeutics (Inst)
Speakers' Bureau - Boehringer Ingelheim (Inst); Deciphera (Inst); PharmaMar (Inst)
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); PharmaMar (Inst); Recordati (Inst); Roche (Inst)
 
Raul Terés
Speakers' Bureau - PharmaMar
Travel, Accommodations, Expenses - Deciphera; PharmaMar; Roche
 
Claudia Valverde Morales
No Relationships to Disclose
 
Richard Riedel
Employment - Limbguard (I)
Leadership - Limbguard (I)
Stock and Other Ownership Interests - Limbguard (I)
Consulting or Advisory Role - AADi; Adaptimmune; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; GlaxoSmithKline; NanoCarrier; Recordati; SpringWorks Therapeutics
Research Funding - AADi (Inst); Arog (Inst); Ayala Pharmaceuticals (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); Intensity Therapeutics (Inst); NanoCarrier (Inst); Oncternal Therapeutics (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); SynOX (Inst); TRACON Pharma (Inst); Trillium Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - PandoNet - Limbguard (I)
Travel, Accommodations, Expenses - Daiichi Sankyo; Deciphera; NanoCarrier; Recordati; SpringWorks Therapeutics
 
Kim Guedes
Employment - Intensity Therapeutics
 
Brian Schwartz
Employment - Intensity Therapeutics
 
Erlinda Gordon
Leadership - Counterpoint Biomedica; Delta Next-Gene, LLC
Stock and Other Ownership Interests - Counterpoint Biomedica; Delta Next-Gene
Research Funding - Jazz Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Co-inventor of patents on targeting pharmaceutical agents to injured tissues
Travel, Accommodations, Expenses - Immix BioPharma
 
Lewis Bender
Employment - Intensity Therapeutics
Leadership - Intensity Therapeutics
Stock and Other Ownership Interests - Intensity Therapeutics
Research Funding - Intensity Therapeutics
 
Christian Meyer
Consulting or Advisory Role - Daiichi Sankyo/UCB Japan; Deciphera; Deciphera; Deciphera; PTC Therapeutics
Speakers' Bureau - Novartis
Other Relationship - UpToDate
(OPTIONAL) Uncompensated Relationships - Chrondrosarcoma Foundation; Desmoid Tumor Research Foundation